Controlling Salmonella in Poultry
Natural Sciences and Engineering Research Council of Canada
- Grant type: Engage Grants Program
- Year: 2015/16
- Total Funding: $25,000
University of Alberta
No researchers found.
Salmonella infections represent a significant public health concern and disease burden. Significant sources of infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is one means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial growers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. has developed a novel antibody-based therapeutic strategy that could prevent and/or eliminate Salmonella pathogens in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and tested for their efficacy using in vitro cell culture methods. The next step requires testing their efficacy in vivo, in pre-harvest chicken flocks. It is imperative to demonstrate that these antibodies, when administered at therapeutic levels in a preventative fashion are capable of eliminating Salmonella, yet have no adverse effects on host physiology or on members of the normal flora. This work capitalizes on the Willing laboratory's expertise in areas of Salmonella pathogenesis and animal physiology. This project proposes to address several critical questions that are essential to the development of NovoBind's anti-Salmonella based therapeutic for livestock: (1) Identify whether NovoBind's antibody-based therapeutic reduces local and systemic Salmonella burdens in poultry, (2) Determine the most effective antibody dose required to limit Salmonella colonization in poultry, (3) Sample the poultry gastrointestinal microbiome to assess the impact of the antibody-based therapy on resident members of the chicken normal flora. The development of a Salmonella-selective, antibody-based therapeutic that has minimal effects on host physiology and normal flora would benefit Canadians and worldwide populations by eliminating a source of antibiotics in the food chain, reducing human infection, illness, loss of life and the costs of treatment.